Medanta – The Medicity
India's #1 ranked hospital offers a fully integrated cancer institute with CyberKnife VSI robotic radiosurgery, CAR-T cell therapy, bone marrow transplant, and organ-specific multidisciplinary tumour boards — all under one roof across 43 acres in the Delhi NCR.
About Medanta – The Medicity
Medanta – The Medicity was founded in 2009 by Dr. Naresh Trehan, one of the world's foremost cardiovascular and cardiothoracic surgeons, with a defining ambition: to bring internationally competitive, evidence-based medicine to Indian patients at accessible costs. Spread across 43 acres in Sector 38, Gurugram, the flagship campus is one of the largest and most integrated private medical complexes in Asia, housing over 1,600 beds, 45 operating theatres, 300+ ICU beds, and a dedicated research and medical education campus — all designed around the concept of a self-contained 'medical city.'
The Medanta Institute of Cancer Care is the hospital's comprehensive oncology division, bringing together medical oncology and haemato-oncology, radiation oncology, and organ-specific surgical oncology within a single multidisciplinary framework. Tumour boards cover breast, lung, brain, head and neck, gastrointestinal, hepatobiliary, genitourinary, gynaecological, and haematological cancers. Advanced treatment capabilities include CyberKnife VSI Robotic Radiosurgery, Varian Edge, Tomotherapy, VMAT and IGRT linear accelerators, an Integrated Brachytherapy Unit, and an active CAR-T cell therapy programme for haematological malignancies. The hospital is also a recognised centre for Bone Marrow Transplant (BMT) for both adult and paediatric patients.
Medanta holds JCI (Joint Commission International), NABH, and NABL accreditations — the most rigorous multi-accreditation portfolio of any private hospital in India. It has been named among Newsweek's World's Best Hospitals for seven consecutive years (2020–2026), ranking as the only Indian private hospital consistently in the global top 150. In 2026, it was ranked the #1 Hospital in India. The hospital has achieved several clinical firsts, including India's first successful intestinal transplant (2013) and the world's highest recorded number of renal robotic transplants — reflecting a culture of systematic innovation.
For international cancer patients, CancerFax acts as a dedicated coordination bridge to Medanta. Our clinical team reviews your medical records, prepares a structured oncology summary for the Medanta tumour board, and coordinates directly with the Institute of Cancer Care to confirm treatment eligibility, obtain cost estimates, schedule consultations, and arrange logistics. This process removes the uncertainty and administrative burden that often delays time-sensitive oncology decisions.
| Hospital at a Glance | |
|---|---|
| Country | India |
| City | Gurugram, Haryana (Delhi NCR) |
| Established | 2009 |
| Hospital Type | Private Multi-Super Speciality |
| Accreditation | JCI · NABH · NABL |
| Beds | 1,600+ |
| Operating Theatres | 45 |
| Research Focus | Oncology, Transplant, Robotic Surgery, CAR-T Therapy |
Why Patients Choose This Hospital
Cancer Specialties and Clinical Departments
Advanced Treatment Capabilities
Our Medical Specialists
Medanta Cancer Institute is staffed by a team of over 800 specialist physicians across the hospital, with the oncology division led by fellowship-trained organ-specific surgical oncologists, haemato-oncologists, radiation oncologists, and medical oncologists — many of whom trained at AIIMS, Tata Memorial Hospital, or international centres in the USA, UK, and Europe. The haemato-oncology division is led by Dr. Nitin Sood (Director, Hemato-Oncology & BMT) and the medical oncology department by Dr. Ashok Kumar Vaid, both nationally recognised figures in their fields.
The Cancer Institute follows a Tumour Board (multidisciplinary group) model for every case, ensuring that surgical, radiation, and systemic treatment decisions are made collaboratively. The team is actively involved in clinical research, protocol development, and early adoption of novel therapies — including CAR-T cell therapy and immunotherapy — in partnership with international institutes of repute.
Patients seeking specific physician consultations or second opinions may request a review through the CancerFax coordination process before confirming travel or admission.
World-Class Infrastructure
- CyberKnife VSI Robotic Radiosurgery System
- Varian Edge Linear Accelerator (SBRT/SRS capable)
- Tomotherapy System
- VMAT and IGRT-enabled Linear Accelerators (×4)
- Integrated Brachytherapy Unit with remote-controlled HDR
- CAR-T Cell Therapy Programme (haematological malignancies)
- Bone Marrow Transplant Unit — adult and paediatric
- Donor Lymphocyte Infusion (DLI) programme
- Dedicated haemato-oncology inpatient unit with HEPA-filtered rooms
- Apheresis and stem cell collection facility
- Next-Generation Sequencing (NGS) for tumour profiling
- 256-Slice CT, 3.0 Tesla MRI, and PET-CT
- Digital pathology and immunohistochemistry laboratory
- NABL-accredited laboratory services
- Liquid biopsy and circulating tumour DNA testing
- da Vinci Robotic Surgical System (prostatectomy, gynaecological, urological)
- 45 operating theatres including intra-operative imaging suite
- Brain Suite (intraoperative MRI for neurosurgery)
- Minimally invasive and laparoscopic cancer surgery across organ sites
- 300+ ICU beds including specialised oncology critical care
Services for International Patients
- arrow_rightGather all available medical records — pathology reports, imaging (CT, MRI, PET-CT), treatment history, and current medications — and share with CancerFax for pre-review before booking.
- arrow_rightAllow CancerFax to prepare a structured oncology summary in the format preferred by Medanta's tumour board — this reduces delays on arrival and ensures your case is reviewed by the right specialist division before your appointment.
- arrow_rightApply for an Indian medical visa ('Medical Attendant Visa' for accompanying family) after receiving the hospital's invitation letter — typically issued within 3–5 working days of confirmed appointment.
CancerFax handles the full pre-arrival coordination with Medanta's International Patient Services team — patients and families do not need to navigate multiple contact points. We remain available throughout your stay and after return.
Patient Amenities & Facilities
Family members accompanying international patients may stay in hospital-affiliated guest houses adjacent to the Medanta campus — bookable through the International Patient Services desk or via CancerFax.
How to Reach This Hospital
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Patient Questions Answered
CancerFax acts as a dedicated coordination layer between you and Medanta's Cancer Institute. The process begins when you send us your medical records — pathology, imaging, treatment history, and any prior second opinions. Our clinical team reviews these, prepares a structured oncology summary in the format expected by Medanta's tumour board, and identifies which specialist division (surgical oncology, haemato-oncology, radiation oncology, etc.) your case should be directed to.
We then contact Medanta's International Patient Services team on your behalf, confirm specialist availability, obtain a treatment cost estimate, and arrange your consultation appointment — either in person or via video conference if you want to speak with the oncologist before committing to travel. Once you decide to proceed, we assist with the medical visa invitation letter, airport transfer coordination, and accommodation near the campus. Throughout your stay and after you return home, CancerFax remains your point of contact for reports, follow-up coordination, and communication with your local oncologist.
Medanta Cancer Institute covers all major solid tumour types — breast, lung, liver, colorectal, head and neck, brain, prostate, gastric, and gynaecological cancers — through organ-specific surgical teams, each supported by a dedicated multidisciplinary tumour board. For haematological malignancies including leukaemia, lymphoma, and myeloma, the haemato-oncology division offers a full spectrum from systemic therapy through to bone marrow transplant and CAR-T cell therapy for eligible patients.
Yes. Medanta Cancer Institute runs an active CAR-T cell therapy programme for eligible patients with relapsed or refractory haematological malignancies, including certain lymphomas and leukaemias. Eligibility is determined by disease type, prior treatment history, performance status, and organ function. CancerFax can review your records and provide an initial assessment of whether your case may meet eligibility criteria before you travel.
Medanta has one of the most comprehensive radiotherapy technology stacks in India, including CyberKnife VSI Robotic Radiosurgery (for cranial, spinal, and body stereotactic treatments), Varian Edge linear accelerator, Tomotherapy, VMAT and IGRT-enabled linear accelerators, and an Integrated Brachytherapy Unit with remote-controlled HDR. This breadth allows the team to select the most appropriate delivery technique for each tumour site and stage.
Medanta – The Medicity is located in Sector 38, Gurugram, approximately 20–30 minutes from Indira Gandhi International Airport (DEL) by car under normal traffic conditions. The hospital's International Patient Services team — and CancerFax on your behalf — can arrange a dedicated airport pickup. Alternatively, the Millennium City Centre metro station on the Delhi Metro Yellow Line is approximately 10 minutes from the campus for patients already in the NCR.
Yes. Medanta holds JCI (Joint Commission International) accreditation — the global gold standard for hospital quality and patient safety — alongside NABH and NABL accreditations. These three accreditations together reflect compliance with international clinical governance, laboratory quality, and safety standards. For international patients, JCI accreditation in particular provides assurance that the hospital meets the same structural and process standards applied to leading hospitals in the USA, Europe, and the Middle East.
Send Your Medical Reports to Medanta – The Medicity via CancerFax
Our clinical team will review your records, prepare a structured summary for Medanta's tumour board, confirm specialist availability, and arrange your consultation — so you arrive with a clear plan, not uncertainty.